Healthcare / Health Information ServicesTSXV
$4.73
+0.49 (+11.56%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-613673.00 · quality 61.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
58/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$253M
P/E
118.3x
↑EV/EBITDA
99.6x
↑ROE
8.6%
↑Gross Margin
25.4%
↓Debt/Equity
0.42
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+102.4%
FCF CAGR
—
FCF margin
-9.6%
FCF / Net income
-2.00x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $35.4M · net income $1.7M · FCF $-3.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $35.4M | $35.4M | $16.0M | $11.5M | $4.3M |
| Net Income | $1.7M | $1.7M | $-405169.00 | $-1.9M | $-6.0M |
| EBITDA | $2.2M | $2.2M | $-224033.00 | $-1.4M | $-6.0M |
| EPS | 0.04 | 0.04 | -0.01 | -0.05 | -1.70 |
| Gross Margin | 25.4% | 25.4% | 35.5% | 43.1% | 43.0% |
| Operating Margin | 6.3% | 6.3% | 1.8% | -12.7% | -45.9% |
| Net Margin | 4.8% | 4.8% | -2.5% | -16.8% | -140.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.42 | 0.42 | — | — | -0.05 |
| Current Ratio | 3.98 | 3.98 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-3.4M | $-3.4M | $-325505.00 | $-613673.00 | $-396121.00 |
| Returns | |||||
| ROE | 8.6% | 8.6% | 22.9% | 105.8% | 1680.1% |
| Valuation | |||||
| P/E | 118.25 | 118.25 | — | — | — |
| EV/EBITDA | 99.57 | 99.57 | — | — | — |
| P/B | 11.25 | 11.25 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | 120.5% | 120.5% | 39.4% | 169.6% | — |
| EPS Growth | 500.0% | 500.0% | 80.0% | 97.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
118.9%
EPS terminal req.
$0.42
Spread vs growth
381.1%
5Y implied EPS CAGR
66.2%
EPS terminal req.
$0.51
Spread vs growth
433.8%
10Y implied EPS CAGR
35.2%
EPS terminal req.
$0.82
Spread vs growth
464.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+157.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.01 → 0.04
Residual
+157.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.